Pluri Inc
PLUR.TA
ILA1 059.00 -3.20%
Exchange: TLV | Sector: Healthcare | Industry: Biotechnology
Q3 2024
Published: Mar 31, 2024

Earnings Highlights

  • Revenue of $0.07M down 18.4% year-over-year
  • EPS of $-1.01 increased by 33.6% from previous year
  • Gross margin of 14.1%
  • Net income of -5.29M
  • "N/A" - N/A
PLUR.TA
Company PLUR.TA

Executive Summary

Pluri Inc reported a USD 71k revenue in QQ3 2024, continuing to operate as a pre-revenue biotechnology company with an outsized R&D and SG&A burden. Despite a small topline, gross profit was USD 10k (gross margin ~14%), and the company posted a net loss of USD 5.29m for the quarter, with an EBITDA of USD -5.11m. The quarterly results reflect the companyโ€™s heavy investment in early-stage placental cell therapy programs (notably PLXPAD in Phase III for hip-fracture muscle recovery and GVHD) and ongoing pipeline development, rather than commercial commercialization. The operating burn persisted, with negative free cash flow of USD -4.29m and a cash burn from operations of USD -4.20m, partially offset by USD 5.69m in maturities/sales of investments during the period, leaving cash and short-term investments at USD 26.28m at quarter-end. The balance sheet shows a high debt burden (long-term debt USD 29.41m; total debt USD 30.08m) and negative equity, implying a leveraged balance sheet even as liquid assets provide runway for continued clinical activities. Management commentary is not available in the provided transcript data, limiting explicit forward-looking guidance from QQ3 2024. Investors should focus on pipeline milestones, potential licensing or partnership opportunities, and the companyโ€™s ability to extend runway through financing while advancing Phase III programs.

Key Performance Indicators

Revenue
Decreasing
71.00K
QoQ: -32.38% | YoY: -18.39%
Gross Profit
Decreasing
10.00K
14.08% margin
QoQ: 100.20% | YoY: -88.51%
Operating Income
Increasing
-5.53M
QoQ: -6.16% | YoY: 22.06%
Net Income
Increasing
-5.29M
QoQ: -7.91% | YoY: 30.57%
EPS
Increasing
-1.01
QoQ: -5.21% | YoY: 33.55%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q3 2025 0.43 -0.94 +501.4% View
Q2 2025 0.19 -0.53 +76.2% View
Q1 2025 0.33 -1.12 +503.7% View
Q4 2024 0.10 -1.06 -13.5% View
Q3 2024 0.07 -1.01 -18.4% View